Efficacy, safety and cycle control of five oral contraceptive regimens containing norgestimate and ethinyl estradiol

Contraception

Volumn 67, Issue 6, 2003, Pages 431-437

  LaGuardia, Katherine D ^a   Shangold, Gary ^b   Fisher, Alan ^a   Friedman, Andrew ^a   Kafrissen, Michael ^a  

^a Ortho McNeil Pharmaceutical Incorporated   (United States)

^b JOHNSON AND JOHNSON   (United States)

Author keywords

Cycle control; Ethinyl estradiol; Norgestimate; Ortho Tri Cyclen ; Ortho Tri Cyclen Lo; Ovulation suppression

Indexed keywords

ETHINYLESTRADIOL PLUS NORGESTIMATE;

ABDOMINAL PAIN; ADULT; ARTICLE; BREAKTHROUGH BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DYSMENORRHEA; FEMALE; HEADACHE; HORMONAL CONTRACEPTION; HUMAN; MASTALGIA; MULTICENTER STUDY; NAUSEA; NORMAL HUMAN; OVULATION INHIBITION; PHASE 2 CLINICAL TRIAL; PROGESTERONE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SINUSITIS; SPOTTING; UPPER RESPIRATORY TRACT INFECTION; UTERINE BLEEDING PATTERN; VOMITING;

EID: 0037838834     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(03)00069-6     Document Type: Article

References (18)

1. th ed:1998;211-247 Ardent Media, Inc, New York.
2. Upmalis D.H., Jaffe M.E., Casper R.F. Receptor dynamics as applied to the delivery of sex steroids. Ann NY Acad Sci. 618:1991;518-521.
3. Kaunitz A.M. Oral contraceptive estrogen dose considerations. Contraception. 58:(Suppl 3):1998;S15-S21.
4. Akerlund M., Rode A., Westergaard J. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol. Br J Obstet Gynaecol. 100:1993;832-838.
5. Rosenberg M.J., Meyers A., Roy V. Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives a randomized trial of 20 micrograms and 35 micrograms estrogen preparations . Contraception. 60:1999;321-329.
6. Rosenberg M.J., Waugh M.S., Meehan T.E. Use and misuse of oral contraceptives risk indicators for poor pill-taking and discontinuation . Contraception. 51:1995;283-288.
7. Rosenberg M.J., Waugh M.S. Oral contraceptive discontinuation a prospective evaluation of frequency and reasons . Am J Obstet Gynecol. 179:1998;577-582.
8. Corson S.L. Efficacy and safety of a monophasic and a triphasic oral contraceptive containing norgestimate. Am J Obstet Gynecol. 170:1994;1556-1561.
9. McGuire J.L., Phillips A., Hahn D.-W., Tolman E.L., Flor S., Kafrissen M.E. Pharmacologic and pharmacokinetic characteristics of norgestimate and its metabolites. Am J Obstet Gynecol. 163:1990;2127-2131.
10. Audet M.C., Moreau M., Koltun W.D., et al. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive a randomized controlled trial . JAMA. 285:2001;2347-2354.
11. London R.S., Chapdelaine A., Upmalis D., Olson W., Smith J. Comparative contraceptive efficacy and mechanism of action of the norgestimate-containing triphasic oral contraceptive. Acta Obstet Gynecol Scand Suppl. 156:1992;9-14.
12. Rabe T., Nitsche D.C., Runnebaum B. The effects of monophasic and triphasic oral contraceptives on ovarian function and endometrial thickness. Eur J Contracept Reprod Health Care. 2:1997;39-51.
13. Israel R., Mishell D.R., Stone S.C., Thorneycroft I.H., Moyer D.L. Single luteal phase serum progesterone assay as an indicator of ovulation. 1972. Am J Obstet Gynecol. 176:1997;490-491.
14. Chapdelaine A., Desmarais J.-L., Derman R.J. Clinical evidence of the minimal androgenic activity of norgestimate. Int J Fertil. 34:1989;347-352.
15. Corson S.L. Efficacy and clinical profile of a new oral contraceptive containing norgestimate. Acta Obstet Gynecol Scand Suppl. 152:1990;25-31.
16. Vallon A.M., Cristol P., Hedon B., Deschamps F. Ovarian suppressive activity of a low dose monophasic oral contraceptive during correct and incorrect pill intake. Contracept Fertil Sex. 20:1992;521-529.
17. Hull M.E., Moghissi K.S. Effects of norgestimate (0.250 mg) in combination with ethinyl estradiol (0.035 mg) on cervical mucus. Adv Contracept. 2:1986;71-77.
18. Eyong E., Buchi K., Elstein M. Effects of 180 μg and 250 μg norgestimate on pituitary-ovarian function and cervical mucus. Fertil Steril. 50:1988;756-760.